Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin Add-on for COVID-19
NCT04343092Phase 1Completed
- Sponsor
- University of Baghdad
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ivermectin in coronavirus disease 2019 (COVID-19), sponsored by University of Baghdad. Primary endpoint: Number of Cured Patients at 4 weeks. Started Apr 2020; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04343092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04343092.